THYMOPENTIN

Cas No: 177966-81-3
Summenformel: $C_{30}H_{49}N_9O_9$
Molekulargewicht: 679.76 g/mol
Source: Synthetic
Synonym: TP-5, Thymopoietin II Fragment (32-36)
Sequenz: H-ARG-LYS-ASP-VAL-TYR-OH, RKDVY
Gegenion: Acetat



Strukturformel von Thymopentin
For Research Use Only.

Thymopentin (TP5), the active site of thymopoietin hormone, has been shown to increase antibody response (HbsAb) following B-hepatitis vaccination in several disease conditions. Uremic patients are at high risk of hepatitis B virus (HBV) infection and, despite the availability and efficacy of hepatitis B vaccine, a high rate of non responders has been reported. TP5 seems an useful therapeutical tool for non responder patients. As it promotes T cell maturation and responsiveness, which are impaired in uremia, it could play a major part in the management of uremic immunodeficiency.
It is also used to boost the immune response in the treatment of other diseases. Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization.

Reference

Pagani S1, Cruciani L, Chianelli M, Procaccini E, Pozzilli P. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients. Diabetes Res. 1989 Dec;12(4):199-201.

Donati D and Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. 1988; 50(2): 133-136.

Genosphere Biotechnologies
21 place de la République
F-75003 Paris
Internet:
www.biomodul.de/peptide.html
E-mail:
info@genosphere-biotech.de